Umeclidinium bromide

Hypersensitivity.

Patient with narrow-angle glaucoma, severe CV disorders, particularly cardiac arrhythmias; urinary retention, prostatic hyperplasia, bladder-neck obstruction. Not recommended in patients with asthma. Not indicated for use as a rescue/initial therapy in acute bronchospasm episodes or with rapidly worsening COPD. Severe hepatic impairment. Pregnancy and lactation.

Significant: Cardiac arrhythmias (e.g. atrial fibrillation, tachycardia); hypersensitivity reactions, including angioedema, anaphylaxis, rash, pruritus and urticaria; exacerbation of urinary retention; may worsen glaucoma (e.g. increased IOP).
Eye disorders: Eye pain, blurred vision.
Gastrointestinal disorders: Constipation, upper abdominal pain, dry mouth, dysgeusia.
Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
Nervous system disorders: Headache.
Renal and urinary disorders: UTI, dysuria.
Respiratory, thoracic and mediastinal disorders: URTI, cough, nasopharyngitis, sinusitis, pharyngitis, dysphonia, oropharyngeal pain.
Potentially Fatal: Paradoxical bronchospasm.

Monitor pulmonary function tests (e.g. FEV₁, peak flow) at baseline and periodically during treatment. Assess for signs or symptoms of glaucoma, urinary retention and hypersensitivity reactions.

Symptoms: Visual accommodation disturbances, dry mouth, and tachycardia.

Management: Symptomatic and supportive treatment.

May result in additive effects with other anticholinergic agents.

Description:
Overview: Umeclidinium bromide is a long-acting muscarinic antagonist (LAMA).
Mechanism of Action: Umeclidinium bromide competitively and reversibly inhibits the binding of acetylcholine at muscarinic type 3 (M₃) receptors in bronchial smooth muscle, leading to bronchodilation.
Pharmacokinetics:
Absorption: Rapidly absorbed from the lungs. Bioavailability: Approx 13%. Time to peak plasma concentration: 5-15 minutes.
Distribution: Plasma protein binding: Approx 89%.
Metabolism: Metabolised in the liver mainly by CYP2D6 via hydroxylation and O-dealkylation, followed by glucuronidation to form several metabolites. Additionally, it is a substrate for P-gp transporter.
Excretion: Elimination half-life: Approx 11-19 hours.

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 11519069, Umeclidinium bromide. https://pubchem.ncbi.nlm.nih.gov/compound/Umeclidinium-bromide. Accessed Nov. 25, 2025.

Store between 15-30°C. Protect from moisture, heat or sunlight.

Antiasthmatic & COPD Preparations

R03BB07 - umeclidinium bromide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, anticholinergics.

Brayfield A, Cadart C (eds). Umeclidinium Bromide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/11/2025.

GlaxoSmithKline NZ Limited. Incruse Ellipta 62.5 micrograms Powder for Inhalation data sheet 25 April 2023. Medsafe. http://www.medsafe.govt.nz. Accessed 05/11/2025.

Incruse Ellipta 55 micrograms Inhalation Powder (GlaxoSmithKline UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 05/11/2025.

Incruse Ellipta Aerosol, Powder (GlaxoSmithKline LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 05/11/2025.

Joint Formulary Committee. Umeclidinium. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/11/2025.

Umeclidinium Bromide. UpToDate Lexidrug, AHFS DI (Adult and Pediatric) Online. American Society of Health-System Pharmacists, Inc. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 05/11/2025.

Umeclidinium. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 05/11/2025.

Umeclidinium. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 05/11/2025.